Skip to main content

Table 1 Baseline clinical characteristics in the group included in 2000 (N = 47)

From: Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis

Baseline clinical characteristics (N = 47)
Clinical characteristics
 Men/women, N/N (%/%) 33/14 (70.2/29.8)
 Age (y), median (IQR) 49 (37–58)
 Primary/revision ESS in 2000, N/N (%/%) 22/25 (46.8/53.2)
 Comorbidity
  Allergic sensitization, N (%) 24 (51.1)
  Asthma, N (%) 18 (38.3)
  AERD, N (%) 11 (23.4)
 Total NP score, median (IQR) 4 (3–6)
 Total symptom score, median (IQR) 8 (7–11)
Tissue biomarkers, median (IQR)
 IL-5 (pg/ml) 133.24 (43.00–338.58)
 Detectable IL-5, N (%) 31 (66.0%)
 IL-5Rα (pg/ml) 5003.01 (1765.61–21,069.23)
 TGF-β1 (pg/ml) 9534.22 (7457.03–20,760.85)
 MPO (ng/ml) 6878.56 (2805.72–14,874.40)
 IL-18 (pg/ml) 15,373.60 (6738.21–22,019.14)
 ECP (mg/l) 7.46 (1.84–14.87)
 Total IgE (kU/l) 432.30 (146.30–1155.90)
 IgE Grass mix 1 (kU/l) 3.88 (0.00–5.78)
 IgE Tree mix 9 (kU/l) 4.30 (0.00–8.03)
 IgE House dust mite mix 2 (kU/l) 4.08 (0.00–8.03)
 Detectable IgE to SAE, N (%) 18 (39.1)
Nasal secretion biomarkers, median (IQR)
 IL-5 (pg/ml) 30.00 (30.00–131.21)
 IL-5Ra (pg/ml) 1135.84 (497.57–5357.62)
 ECP (mg/l) 0.53 (0.25–1.16)
 IgE (kU/l) 283.44 (109.38–440.85)
Serum biomarkers, median (IQR)
 IL-5 (pg/ml) BDL
 IL-5Ra (pg/ml) 414.90 (297.00–744.70)
 ECP (µg/l) 26.10 (21.00–40.00)
 IgE (kU/l) 157.0 (48.5–278.0)
  1. N number, IQR interquartile range, BDL below detection level